3/3
01:06 pm
zyme
Zymeworks (ZYME) had its price target raised by Stifel Nicolaus from $40.00 to $47.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks (ZYME) had its price target raised by Stifel Nicolaus from $40.00 to $47.00. They now have a "buy" rating on the stock.
3/3
11:24 am
zyme
Zymeworks (ZYME) had its price target raised by Leerink Partners from $52.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Zymeworks (ZYME) had its price target raised by Leerink Partners from $52.00 to $58.00. They now have an "outperform" rating on the stock.
3/2
09:28 pm
zyme
Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028 [Seeking Alpha]
Medium
Report
Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028 [Seeking Alpha]
3/2
12:52 pm
zyme
Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/2
10:55 am
zyme
Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]
3/2
06:18 am
zyme
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]
Low
Report
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]
3/2
06:01 am
zyme
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Low
Report
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
3/2
06:00 am
zyme
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2/12
06:00 am
zyme
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Low
Report
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
1/27
06:00 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Low
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
1/23
05:09 am
zyme
Zymeworks (NASDAQ:ZYME) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zymeworks (NASDAQ:ZYME) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
06:17 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
1/12
06:00 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
1/11
07:40 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
1/11
06:00 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026
1/6
02:47 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
1/6
01:34 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
12/29
07:21 am
zyme
3 Stocks Estimated To Be Priced Below Value In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Priced Below Value In December 2025 [Yahoo! Finance]
12/26
07:07 pm
zyme
3 Stocks Estimated To Be Undervalued In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Undervalued In December 2025 [Yahoo! Finance]
12/26
06:56 am
zyme
Three Companies Estimated To Be Trading Below Their Intrinsic Value [Yahoo! Finance]
Low
Report
Three Companies Estimated To Be Trading Below Their Intrinsic Value [Yahoo! Finance]
12/25
01:06 pm
zyme
3 Stocks Estimated To Be Trading At Discounts Of 23.1% To 41.2% [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Trading At Discounts Of 23.1% To 41.2% [Yahoo! Finance]
12/25
07:06 am
zyme
3 Stocks Estimated To Be Trading At Discounts Of 21.2% To 35.3% Below Intrinsic Value [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Trading At Discounts Of 21.2% To 35.3% Below Intrinsic Value [Yahoo! Finance]
12/24
01:07 pm
zyme
Discover 3 Stocks Including Atour Lifestyle Holdings That May Be Trading Below Estimated Value [Yahoo! Finance]
Neutral
Report
Discover 3 Stocks Including Atour Lifestyle Holdings That May Be Trading Below Estimated Value [Yahoo! Finance]
12/23
12:57 pm
zyme
3 Stocks That May Be Priced Below Their Estimated Worth In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks That May Be Priced Below Their Estimated Worth In December 2025 [Yahoo! Finance]
12/22
01:01 pm
zyme
3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025 [Yahoo! Finance]
Low
Report
3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025 [Yahoo! Finance]